Relmada Therapeutics Inc (NAS:RLMD)
$ 3.05 -0.06 (-1.93%) Market Cap: 92.03 Mil Enterprise Value: 10.23 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 31/100

Q4 2023 Relmada Therapeutics Inc Earnings Call Transcript

Mar 19, 2024 / 08:30PM GMT
Release Date Price: $5.37 (-2.72%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics, Inc. Fourth Quarter and Full Year 2022 Results Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, a recording needed assistance, please press star zero for the operator, and this call is being recorded on Tuesday, March 19th, 2024.

I would now like to turn the conference over to Tim McCarthy. Thank you. Please go ahead.

Tim McCarthy
LifeSci Advisors, LLC - Investor Relations

Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa; and Chief Financial Officer, Maged Shenouda. This afternoon Relmada issued a press release providing a business update announcing financial results for the three and 12 months ended December 31st, 2023.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot